IP Library › Granted Patent US 7,772,245
Granted Patent B2
US 7,772,245 · App. 11/354,594 · Granted Aug 10, 2010

Inhibitors of histone deacetylase

Assignee: Miikana Therapeutics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,772,245
App. No.
11/354,594
Granted
Aug 10, 2010
Kind
B2
Abstract

Disclosed are compounds of formula I that inhibit histone deacetylase (HDAC) enzymatic activity, pharmaceutical compositions comprising such compounds, as well as methods to treat conditions, particularly proliferative conditions, mediated at least in part by HDAC, wherein A, W, W 1 , W 2 , Ar 2 , and G are described herein.

Claims (113)

1. A compound of formula I:

wherein

and the ring containing W 1 and W to which it is fused together form an optionally substituted 1,3,4,9-tetrahydro-2H-b-carbolin-2-yl or an optionally substituted 1,3,4,4a,9,9a-hexahydro-2H-b-carbolin-2-yl substituent;

W 2 is a bond or [—C(R 1 )(R 2 )—] p ;

R 1 and R 2 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic;

p is 1, 2, 3 or 4;

wherein Ar 2 -G-C(O)NHOH, is 5-[-G-C(O)NHOH]-pyrimid-2-ylene

G is a bond; or

a tautomer, stereoisomer, prodrug, or pharmaceutically acceptable salt thereof.

2. The compound according to claim 1 , wherein W 2 is a bond.

3. The compound according to claim 2 , wherein said compound is:

[N-hydroxy-2-(1,3,4,9-tetrahydro-2H-b-carbolin-2-yl)pyrimidine-5-carboxamide],

[N-hydroxy-2-(6-methoxy-1,3,4,9-tetrahydro-2H-b-carbolin-2-yl)pyrimidine-5-carboxamide],

[N-hydroxy-2-(8-methyl-1,3,4,9-tetrahydro-2H-b-carbolin-2-yl)pyrimidine-5-carboxamide],

[N-hydroxy-2-(7-fluoro-1,3,4,9-tetrahydro-2H-b-carbolin-2-yl)pyrimidine-5-carboxamide],

[N-hydroxy-2-(6-fluoro-1,3,4,9-tetrahydro-2H-b-carbolin-2-yl)pyrimidine-5-carboxamide],

[N-hydroxy-2-(6-benzyloxy-1,3,4,9-tetrahydro-2H-b-carbolin-2-yl)pyrimidine-5-carboxamide],

[N-hydroxy-2-(7-methyl-1,3,4,9-tetrahydro-2H-b-carbolin-2-yl)pyrimidine-5-carboxamide],

[N-hydroxy-2-(6-methyl-1,3,4,9-tetrahydro-2H-b-carbolin-2-yl)pyrimidine-5-carboxamide],

[N-hydroxy-2-{6-[3-(morpholin-4-ylmethyl)phenyl]-1,3,4,9-tetrahydro-2H-b-carbolin-2-yl}pyrimidine-5-carboxamide],

[N-hydroxy-2-{6-[3-((4-methylpiperazin-1-yl)methyl)phenyl]-1,3,4,9-tetrahydro-2H-b-carbolin-2-yl}pyrimidine-5-carboxamide],

[N-hydroxy-2-{6-[4-((4-methylpiperazin-1-yl)methyl)phenyl]-1,3,4,9-tetrahydro-2H-b-carbolin-2-yl}pyrimidine-5-carboxamide],

[N-hydroxy-2-{6-[2-((4-methylpiperazin-1-yl)methyl)phenyl]-1,3,4,9-tetrahydro-2H-b-carbolin-2-yl}pyrimidine-5-carboxamide],

[N-hydroxy-2-{9-[2-pyrrolidin-1-ylethyl]-1,3,4,9-tetrahydro-2H-b- carbolin-2-yl}pyrimidine-5-carboxamide],

[N-hydroxy-2-[9-(2-piperidin-1-ylethyl)-1,3,4,9-tetrahydro-2H-b-carbolin-2-yl]pyrimidine-5-carboxamide],

[N-hydroxy-2-[9-(2-morpholin-4-ylethyl)-1,3,4,9-tetrahydro-2H-b- carbolin-2-yl]pyrimidine-5-carboxamide],

[N-hydroxy-2-[9-(phenylsulfonyl)-1,3,4,9-tetrahydro-2H-b-carbolin-2-yl]pyrimidine-5-carboxamide],

[N-hydroxy-2-(9-methyl-1,3,4,9-tetrahydro-2H-b-carbolin-2-yl)pyrimidine-5-carboxamide],

[N-hydroxy-2-(9-benzyl-1,3,4,9-tetrahydro-2H-b-carbolin-2-yl)pyrimidine-5-carboxamide],

[2-(9-acetyl-1,3,4,9-tetrahydro-2H-b-carbolin-2-yl)-N-hydroxypyrimidine-5-carboxamide],

[N-hydroxy-2-{9-[2-pyrrolidin-1-ylmethyl]-1,3,4,9-tetrahydro-2H-b-carbolin-2-yl}pyrimidine-5-carboxamide],

[N-hydroxy-2-[9-(2-hydroxyethyl)-1,3,4,9-tetrahydro-2H-b-carbolin-2-yl]pyrimidine-5-carboxamide],

[N-hydroxy-2-[9-(1-methylpiperidin-3-yl)-1,3,4,9-tetrahydro-2H-b-carbolin-2-yl]pyrimidine-5-carboxamide] or

[N-hydroxy-2-(6-methyl-1,3,4,4a,9,9a-hexahydro-2H-b-carbolin-2-yl)pyrimidine-5-carboxamide].

4. A compound of formula I:

wherein

and the ring containing W 1 and W to which it is fused together form an optionally substituted 1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl or an optionally substituted 1,1a,3,4,4a,5-hexahydro-2H-pyrido[4,3-b]indol-2-yl substituent;

W 2 is a bond or [-C(R 1 )(R 2 )—] p ;

R 1 and R 2 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic;

p is 1, 2, 3 or 4;

wherein Ar 2 -G-C(O)NHOH, is 5-[-G-C(O)NHOH]-pyrimid-2-ylene G is a bond; or

a tautomer, stereoisomer, prodrug, or pharmaceutically acceptable salt thereof.

5. The compound according to claim 4 , wherein W 2 is a bond.

6. The compound according to claim 5 , wherein said compound is:

[N-hydroxy-2-(1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl)pyrimidine-5-carboxamide],

[N-hydroxy-2-(8-methyl-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl)pyrimidine-5-carboxamide],

[2-(8-chloro-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl)-N-hydroxypyrimidine-5-carboxamide],

[2-(8-bromo-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl)-N-hydroxypyrimidine-5-carboxamide],

[N-hydroxy-2-[8-(trifluoromethoxy)-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl]pyrimidine-5-carboxamide],

[N-hydroxy-2-(8-phenyl-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl)pyrimidine-5-carboxamide].

[N-hydroxy-2-(8-fluoro-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl)pyrimidine-5-carboxamide],

[N-hydroxy-2-(8-methoxy-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl)pyrimidine-5-carboxamide],

[N-hydroxy-2-(7-fluoro-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl)pyrimidine-5-carboxamide],

[N-hydroxy-2-(7-methyl-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl)pyrimidine-5-carboxamide],

[N-hydroxy-2-(7,8-dimethyl-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl)pyrimidine-5-carboxamide],

[N-hydroxy-2-(7-chloro-8-methyl-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl)pyrimidine-5-carboxamide],

[N-hydroxy-2-(7-bromo-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl)pyrimidine-5-carboxamide],

[N-hydroxy-2-(8-trifluoromethyl-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl)pyrimidine-5-carboxamide],

[N-hydroxy-2-(9-chloro-8-methyl-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl)pyrimidine-5-carboxamide],

[N-hydroxy-2-(8-nitro-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl)pyrimidine-5-carboxamide].

[N-hydroxy-2-(8-(N-acetamido)-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl)pyrimidine-5-carboxamide],

[N-hydroxy-2-(8-(N-methylsulfonamido)-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl)pyrimidine-5-carboxamide],

[N-hydroxy-2-(8-amino-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl)pyrimidine-5-carboxamide],

[N-hydroxy-2-{8-isopropyl-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],

[N-hydroxy-2-{8-tert-butyl-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],

[N-hydroxy-2-{7-phenyl-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],

[N-hydroxy-2-{5-acetyl-8-methyl-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],

[N-hydroxy-2-(8-methyl-1,3,4,4a,5,9b-hexahydro-2H-pyrido[4,3-b]indol-2-yl)pyrimidine-5-carboxamide] or

[N-hydroxy-2-{8-[(4-methylpiperazin-1-yl)methyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide].

7. The compound according to claim 4 , wherein said compound is:

[N-hydroxy-2-{8-[3-(pyrrolidin-1-ylmethyl)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],

[N-hydroxy-2-{8-(pyridin-3-yl)-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],

[N-hydroxy-2-{8-[4-(pyrrolidin-1-ylmethyl)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],

[N-hydroxy-2-{8-(pyrimidin-5-yl)-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],

[N-hydroxy-2-{8-[3-(morpholin-4-ylmethyl)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],

[N-hydroxy-2-{8-[3-(piperidin-1-ylmethyl)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],

[N-hydroxy-2-{8-[3-(N,N-dimethylaminomethyl)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],

[N-hydroxy-2-{8-[3-((4-hydroxymethylpiperidin-1-yl)methyl)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],

[N-hydroxy-2-{8-[3-(thiomorpholin-4-ylmethyl)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],

[N-hydroxy-2-{8-[3-(N,N-di(2-hydroxyethyl)aminomethyl)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],

[N-hydroxy-2-{8-[3-((4-methylpiperazin-1-yl)methyl)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],

[N-hydroxy-2-{8-[3-(piperazin-1-ylmethyl)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],

[N-hydroxy-2-{8-[3-((4-(methylsulfonyl)piperazin-1-yl)methyl)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],

[N-hydroxy-2-{8-[3-((4-acetylpiperazin-1-yl)methyl)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],

[N-hydroxy-2-{8-[4-(morpholin-4-ylmethyl)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],

[N-hydroxy-2-{8-[4-(thiomorpholin-4-ylmethyl)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],

[N-hydroxy-2-{8-[4-((4-methylpiperazin-1-yl)methyl)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],

[N-hydroxy-2-{8-[4-(hydroxymethyl)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],

[N-hydroxy-2-{8-[5-((4-methylpiperazin-1-yl)methyl)-2-furyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],

[N-hydroxy-2-{8-[5-(morpholin-4-yl)methyl-2-furyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],

[N-hydroxy-2-{8-[5-((4-methylpiperazin-1-yl)methyl)-thien-2-yl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],

[N-hydroxy-2-{8-[3-(hydroxymethyl)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],

[N-hydroxy-2-{8-[4-methoxyphenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],

[N-hydroxy-2-{8-[4-methylphenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],

[N-hydroxy-2-{8-[4-(N-acetamido)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],

[N-hydroxy-2-{8-(fur-2-yl)-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],

[N-hydroxy-2-{8-[3-(pyrrolidin-1-ylcarbonyl)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],

[N-hydroxy-2-{7-[3-(pyrrolidin-1-ylmethyl)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],

[N-hydroxy-2-{8-[3-aminophenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],

[N-hydroxy-2-{8-[3-fluorophenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],

[N-hydroxy-2-{8-[4-fluorophenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],

[N-hydroxy-2-{8-[fur-3-yl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],

[N-hydroxy-2-{8-[1H-pyrrol-2-yl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],

[N-hydroxy-2-{8-[3-(methylthio)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],

[N-hydroxy-2-{8-[4-dimethylaminophenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],

[N-hydroxy-2-{8-[3-(methylsulfinyl)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],

[N-hydroxy-2-{8-[3-(N-acetamidomethyl)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],

[N-hydroxy-2-{8-[3-(N-methylsulfonamidomethyl)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],

[N-hydroxy-2-{8-[3-(N-acetamido)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],

[N-hydroxy-2-{8-[3-(N-methylsulfonamido)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide],

[N-hydroxy-2-{8-[3-(1H-tetrazol-5-yl)phenyl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide] or

[N-hydroxy-2-{8-[thien-2-yl]-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indol-2-yl}pyrimidine-5-carboxamide].

8. A pharmaceutical composition comprising an effective amount of one or more compounds according to claim 1 or claim 4 and a pharmaceutically inert carrier.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 16, 2006
From: ANANDAN, SAMPATH K.; XIAO, XIAO-YI; WARD, JOHN S.; PATEL, DINESH V.
To: MIIKANA THERAPEUTICS, INC.
Reel/Frame 017912/0150 →
Continuity (2)
Provisional Application 6065287000 · Feb 14, 2005
Related Publication 20060199829A1 · Sep 7, 2006